Key takeaways
- Telehealth platform Quel has launched as the first digital health program dedicated to prescribing GLP-1s off-label for substance use disorders.
- The service is built on a treatment protocol piloted at Pennsylvania’s Caron Treatment Centers and is available to buyers in 41 states.
- Prescriptions for addictions targeting alcohol, opioids, and food noise will be written off-label, as the FDA has not approved GLP-1s for this indication.
- This expansion shifts the online GLP-1 intake process from BMI-centric screening to comprehensive behavioral health evaluations.
The clinical utility of GLP-1 medications is expanding far beyond weight loss and diabetes management. In a significant shift for the digital health sector, online medical platforms are now positioning these blockbuster medications as tools to combat substance use disorders.
This behavioral expansion changes the target audience and clinical intake process for online buyers in the United States, offering a structured medical pathway for those looking to curb addictive behaviors off-label.
What happened
On September 8, 2026, a new telemedicine company named Quel announced its launch as the first digital health venture built specifically around prescribing GLP-1 medications for addiction. Operating in 41 states, the platform is an extension of a treatment protocol initially developed and piloted at Caron Treatment Centers, an addiction treatment facility in Pennsylvania. Because the Food and Drug Administration (FDA) has not officially approved GLP-1 receptor agonists to treat substance use disorders, Quel and its clinical team will prescribe these medications off-label to target addictions related to alcohol, opioids, food, and other compulsive behaviors.
Why it matters
This development marks a major clinical and marketing pivot for the telehealth industry, which has spent years focusing almost exclusively on cosmetic weight loss and metabolic health. For US buyers, this expansion means online clinical intake forms, patient screening, and medical support protocols are evolving to address complex behavioral health issues alongside physical weight management.
It also signals growing clinical confidence in the neurological effects of GLP-1s. While early adopters frequently reported a spontaneous reduction in "food noise" and cravings for alcohol, nicotine, or shopping, patients can now seek out telemedicine platforms explicitly for these compulsive struggles. However, because this treatment path is entirely off-label, cash-paying patients must navigate a landscape without standard insurance coverage or FDA-approved dosing guidelines for addiction.
What the data says
The clinical foundation for prescribing GLP-1s like semaglutide (the active ingredient in Ozempic and Wegovy) or tirzepatide (Mounjaro and Zepbound) for addiction is rooted in rapidly accumulating research:
- Expanding clinical trials: While early treatment programs operated with very limited clinical data, dozens of clinical trials are now underway globally to evaluate how GLP-1s affect substance use, with a heavy emphasis on alcohol use disorder.
- Brain chemistry mechanisms: Researchers believe GLP-1 receptors in the brain's reward centers influence dopamine signaling, helping to blunt the "reward" feeling associated with addictive substances and behaviors.
- Lack of FDA approval: The FDA has not approved any GLP-1 drug for addiction or substance use. Consequently, all online prescribing for this indication is off-label, meaning clinicians rely on professional judgment to determine appropriate dosages.
- Regulatory scrutiny: The launch comes amidst heightened regulatory awareness. For example, the FDA recently issued warning letters to international suppliers like Shoolin Pharma in India—which exports raw active pharmaceutical ingredients to US compounding pharmacies—citing unsanitary manufacturing conditions, highlighting the ongoing safety considerations for buyers utilizing compounded alternatives.
How it compares
For consumers comparing online options on our providers page, the emergence of addiction-focused GLP-1 programs introduces a distinct model of care compared to traditional weight-loss platforms:
- Screening and Intake: Standard weight-loss platforms primarily screen patients based on Body Mass Index (BMI) and metabolic comorbidities. Addiction-focused programs like Quel pivot their clinical questionnaires toward behavioral health, substance history, and psychological safety.
- Integration with therapy: While typical weight-loss subscriptions might offer basic nutritional coaching, treating substance use requires integration with mental health support and behavioral therapy to ensure patient safety.
- Medication choice: Patients seeking these treatments online are typically prescribed compounded semaglutide or tirzepatide due to the lower out-of-pocket costs, as brand-name alternatives like Ozempic, Wegovy, or Zepbound can exceed $1,000 per month without insurance. To see how these options match up, consumers can review our analysis of compounded vs. brand-name semaglutide.
How this fits the bigger picture
The rise of telehealth programs targeting behavioral addictions is part of a broader trend where GLP-1 therapy is being recognized for its systemic, multi-organ benefits. Clinicians are increasingly looking past the scale to address conditions that span from pulmonary health to psychiatric care.
This clinical evolution mirrors findings we have tracked across other medical specialties. For instance, recent observational data highlighted in our report on GLP-1s and asthma reduction demonstrated a 14% drop in respiratory flare-ups among patients using these drugs, proving their systemic anti-inflammatory reach.
Furthermore, this pivot toward addiction treatment aligns with a massive surge in psychiatric prescribing. As we detailed in our coverage of GLP-1 prescribing in serious mental illness, prescriptions for patients managing complex psychiatric conditions surged 500% between 2018 and 2024. As providers gain clinical confidence in prescribing these metabolic hormones to patients with complex mental health profiles, the transition into formal telemedicine programs for addiction represents a natural, albeit highly specialized, next step.
What happens next
As Quel rolls out its services across its 41-state footprint, the telehealth industry will monitor patient outcomes and safety metrics closely. Because addiction recovery involves high psychiatric risks, the success of this model will heavily depend on how effectively online platforms can monitor patients virtually.
Over the next few years, results from several ongoing randomized controlled trials evaluating semaglutide and tirzepatide for alcohol and nicotine addiction are expected to read out. Positive data from these trials could eventually pave the way for manufacturers to seek official FDA approval for substance use disorders. Until then, US buyers looking to curb cravings through online platforms will continue to rely on off-label prescribing, cash-pay models, and compounded formulations.
Disclaimer: CompareRx does not provide medical advice. Consult a qualified healthcare professional before beginning any new medication or treatment program for substance use or weight management.